Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tryptophan-naphthoquinone (3c) is a synthetic small molecule derivative consisting of a 1,4-naphthoquinone moiety coupled with the amino acid tryptophan. Developed as a potential antineoplastic agent, it is synthesized using microwave-assisted methods to improve yield and reaction time. The compound's primary mechanism of action involves redox cycling of the quinone group, leading to the generation of reactive oxygen species (ROS) and subsequent oxidative stress-induced cytotoxicity. In preclinical in vitro studies, 3c has shown significant antiproliferative activity against various cervical cancer cell lines, including HPV-positive (SiHa, CaLo) and HPV-negative (C33-A) types, while exhibiting lower toxicity toward non-tumorigenic immortalized keratinocytes (HaCaT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tryptophan-naphthoquinone (3c).